Harbour BioMed signed a discovery and development collaboration with Bristol Myers Squibb centered on next‑generation multispecific antibodies, with up to $90 million in upfront and early payments and potential milestones exceeding $1 billion. Harbour will deploy its Harbour Mice platform and may accelerate early clinical work in China, while BMS brings global development and commercialization scale. The agreement is one of several deals Harbour completed this year, reflecting growing strategic interest from large pharmas in multispecific and next‑generation biologic modalities.